GlassScriptPhysician profile
Lena Dang
NPI 1396573259
$1,242.90
in general payments reported to CMS, 2019-2025
27 companies · $915 in 2025
The $915 reported for 2025 was more than what 85% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $328 · 2025: $915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,242.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $256.41 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Bioprotect Medical, INC. | $237.24 | 2024-2025 | Bioprotect Balloon Implant System |
| Lilly USA, LLC | $152.41 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Abbott Laboratories | $57.66 | 2025 | Freestyle Libre 3 |
| Inspire Medical Systems, INC. | $54.60 | 2025 | Inspire |
| Amgen INC. | $53.15 | 2024-2025 | Repatha, Prolia, Evenity |
| Abbvie INC. | $41.56 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.98 | 2024-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $34.47 | 2025 | |
| Boston Scientific Corporation | $27.42 | 2024 | Watchman Flx |
| Medtronic, INC. | $25.94 | 2025 | Inceptiv |
| C2n Diagnostics, LLC | $25.86 | 2025 | Precivityad2 |
| Vanda Pharmaceuticals INC. | $22.01 | 2024 | Fanapt |
| Mannkind Corporation | $20.79 | 2024 | |
| Pfizer INC. | $17.88 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $17.72 | 2025 | Sunosi |
| Kyowa Kirin, INC. | $17.72 | 2025 | |
| Edwards Lifesciences Corporation | $17.09 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Otsuka America Pharmaceutical, INC. | $16.82 | 2024 | Rexulti |
| Merck Sharp & Dohme LLC | $15.92 | 2025 | Gardasil 9, Capvaxive |
| Seqirus USA INC | $15.29 | 2025 | Flucelvax, Fluad |
| Esperion Therapeutics, INC. | $14.80 | 2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $14.62 | 2024 | Farxiga |
| Dexcom, INC. | $14.38 | 2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $14.01 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.78 | 2025 | Trintellix |
| Phathom Pharmaceuticals, INC. | $8.37 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lena Dang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.